ProQR Therapeutics N.V. PRQR 深 沪
等待开盘 04-03 09:30:00 美东时间
1.71
0.000
0.00%
华盛通- 最 高1.74
- 今 开1.70
- 成交量 24.10万股
- 最 低 1.63
- 昨 收 1.71
- 总市值 1.80亿
- 52周最高 3.10
- 市盈率 静 --
- 换手率 0.23%
- 52周最低 1.08
- 委 比 -35.35%
- 总股本 1.05亿
- 历史最高 27.60
- 量 比 0.31
- 振 幅 6.43%
- 历史最低 0.53
- 每 手 1
- 风险率 0.39%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026
ProQR Therapeutics will host a virtual event on April 8, 2026, to discuss its RNA editing pipeline beyond AX-0810, including new programs and clinical data updates. The event will feature presentations and a Q&A session. ProQR's Axiomer™ technology uses ADAR to edit RNA, correcting mutations and potentially treating various diseases. Learn more at www.proqr.com or register at the provided link.
03-25 12:00
ProQR Therapeutics Q4 EPS $(0.09) Misses $(0.08) Estimate, Sales $5.458M Miss $8.550M Estimate
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 10 percent increase over losses of $(0.10) per share from
03-13 06:17
ProQR Announces Year End 2025 Operating and Financial Results
ProQR Therapeutics reported advancements in its RNA editing platform, including Phase 1 dosing for AX-0810, selection of development candidates AX-2402 for Rett syndrome, and AX-2911 for MASH, and achieved $4.5 million in Lilly collaboration milestones in 2025. The company ended 2025 with €92.4 million in cash, supporting operations into mid-2027. AX-0810 target engagement data is expected in early 2026, with plans to expand trials to include PSC...
03-12 11:00
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Relmada Therapeutics (NASDAQ:RLMD) stock rose 48.3% to $6.6 during Mon...
03-09 20:05
ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference
ProQR Therapeutics N.V. will present at the Citizens Life Sciences Conference on March 11, 2026, to discuss its Axiomer™ RNA editing technology, a next-generation approach using ADAR to correct RNA mutations, offering potential new treatments for diverse diseases.
03-03 21:30
ProQR Announces Planned Changes to Board Composition
ProQR Therapeutics announced that Dinko Valerio and Alison Lawton will step down from its Board at the 2026 Annual General Meeting as their terms end. The changes reflect the company's growth and commitment to strong governance and succession planning. The Board thanks them for their significant contributions and efforts that have impacted ProQR's development. ProQR is advancing its RNA therapy platform, Axiomer™, which uses the body's ADAR enzym...
02-09 13:00
ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook
ProQR Therapeutics reported progress in advancing its pipeline programs, including positive early safety and pharmacokinetic data for AX-0810 and selection of development candidates for AX-2402 and AX-2911. Strategic collaboration milestones with Eli Lilly further strengthened the company’s financial position.
01-08 13:00
ProQR to Participate in 8th Annual Evercore Healthcare Conference
ProQR Therapeutics will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 4, 2025. The company highlights its Axiomer™ RNA editing technology, which uses ADAR to make precise RNA edits, potentially treating diseases caused by RNA mutations. ProQR focuses on developing RNA therapies for rare and prevalent diseases. Webcast details are available on their website, and an archive will be accessible for 30 day...
2025-12-01 13:00
ProQR Therapeutics Q3 EPS $(0.10), Inline, Sales $2.882M Miss $8.550M Estimate
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 9.09 percent increase over losses of $(0.11) per share from the same period last year.
2025-11-06 20:16
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
2025-11-05 10:35
